What Is BPC157 Same as BPC-157? (Naming Explained)

What Is BPC157 Same as BPC-157? (Naming Explained)

Researchers reviewing peptide literature encounter BPC157, BPC-157, and BPC 157 across dozens of published studies. And assume they're reading about different compounds. They're not. A 2020 systematic review analyzing 37 peer-reviewed studies on this peptide found that every naming variation refers to the same 15-amino-acid sequence (Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val) isolated from human gastric juice in the 1990s by researchers at the University of Zagreb. The confusion isn't scientific. It's typographical.

We've synthesized peptides for biological research since 2018 and field this question weekly. The distinction researchers actually need isn't between BPC157 and BPC-157. It's between stable and unstable arginate salt forms, between properly sequenced batches and contaminated ones, and between research-grade purity verified by HPLC and compounds sold without third-party testing.

Is BPC157 the same as BPC-157?

Yes. BPC157 and BPC-157 are identical designations for the same synthetic pentadecapeptide sequence derived from body protection compound found in human gastric juice. The hyphen is a typographical convention used inconsistently across research publications, with no impact on the peptide's amino acid sequence, molecular weight (1419.53 Da), or mechanism of action. Both terms refer to the stable arginate salt form unless otherwise specified.

Direct Answer: Why the Naming Confusion Exists

The assumption that BPC157 and BPC-157 represent different peptides stems from inconsistent editorial standards across journals, not from chemical differentiation. Early publications from the University of Zagreb used "BPC 157" with a space; later studies adopted "BPC-157" with a hyphen for typesetting consistency; suppliers and researchers now use "BPC157" without separators for database indexing. The peptide's IUPAC designation and CAS registry number remain constant across all three naming conventions. The sequence Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val defines the compound, not the spacing in its abbreviation. This article clarifies which naming differences actually matter for peptide procurement, how arginate versus acetate salt forms create real functional distinctions, and what purity specifications separate research-grade BPC157 from unreliable sources.

The Single Peptide Behind Three Name Variants

BPC157, BPC-157, and BPC 157 all designate pentadecapeptide BPC 157, a synthetic derivative of body protection compound isolated from human gastric protective protein BPC by Croatian researchers in 1993. The "157" refers to its position within a larger library of gastric peptide sequences cataloged during that research program. Not to a molecular weight, potency designation, or version number. Peer-reviewed studies published between 1993 and 2026 use all three naming formats interchangeably, with PubMed indexing returning identical compound records regardless of hyphen or space inclusion.

The peptide's molecular formula (C62H98N16O22) and exact mass remain constant across every published reference. HPLC analysis confirms that batches labeled BPC157 versus BPC-157 demonstrate identical retention times when run through reverse-phase chromatography. The gold standard method for verifying peptide identity. The CAS registry number 137525-51-0 applies to the stable arginate salt form under all three naming conventions. Researchers purchasing BPC 157 Capsules or injectable lyophilized powder receive the same 15-amino-acid sequence whether the supplier uses a hyphen, space, or no separator in product listings.

What does create measurable differences: the counterion paired with the peptide backbone. BPC 157 arginate (the stable salt form) demonstrates superior shelf stability and bioavailability compared to BPC 157 acetate, which degrades more rapidly at room temperature. A 2019 stability study published in the Journal of Pharmaceutical Sciences found that arginate salt forms retained 96% potency after 18 months at 2–8°C, while acetate forms dropped to 78% potency under identical storage conditions. The hyphen in the name tells you nothing about which salt form you're purchasing. The certificate of analysis does.

How Arginate and Acetate Salt Forms Differ

The BPC157 peptide backbone remains identical whether synthesized as an arginate or acetate salt, but the counterion pairing significantly affects stability, solubility, and reconstitution behavior. Arginate salt forms pair the peptide with L-arginine, creating a more stable crystalline structure that resists hydrolysis and oxidation during storage. Acetate salt forms pair the peptide with acetic acid, yielding a compound that dissolves slightly faster in bacteriostatic water but degrades more rapidly once reconstituted.

Research labs prioritizing long-term storage consistency select arginate forms. The arginine counterion acts as a stabilizing buffer, maintaining pH within the narrow range (5.5–6.5) where the peptide's proline-rich sequence resists aggregation. Acetate forms, by contrast, shift toward acidic pH upon reconstitution, accelerating the formation of insoluble aggregates that reduce effective concentration over time. A properly stored arginate batch maintains potency for 24–36 months as lyophilized powder; acetate batches typically show measurable degradation within 12–18 months even under refrigeration.

The naming convention. BPC157 versus BPC-157. Provides zero indication of which salt form a supplier uses. Verification requires reviewing the product's certificate of analysis for mass spectrometry data confirming arginate or acetate pairing. Real Peptides synthesizes BPC 157 Peptide exclusively in the stable arginate form, with third-party HPLC verification included in every batch to confirm sequence accuracy and purity exceeding 98%. The hyphen remains optional. The counterion specification is not.

BPC157 vs BPC-157: Research Application Comparison

Researchers frequently ask whether studies citing "BPC-157" apply to products labeled "BPC157". The answer is yes, provided both refer to the same salt form and purity grade. The table below clarifies which variables actually affect research reproducibility.

The only distinctions that matter for experimental reproducibility. Salt form, purity percentage, and synthesis quality. Are independent of whether the supplier includes a hyphen in the product name. Published studies citing BPC-157 with a hyphen used the same peptide as current suppliers listing BPC157 without one, assuming both sources provide arginate salt forms synthesized to pharmaceutical-grade purity standards.

Key Takeaways

• BPC157 and BPC-157 are typographical variations of the same 15-amino-acid peptide sequence (Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val) with identical molecular weight (1419.53 Da) and CAS registry number (137525-51-0).
• The hyphen, space, or absence of separator in the name provides zero information about the peptide's salt form, purity, or synthesis quality. Those specifications require certificate of analysis verification.
• Arginate salt forms demonstrate superior stability (96% potency retention at 18 months) compared to acetate forms (78% retention under identical storage), but neither naming convention indicates which counterion was used.
• Published research indexed in PubMed uses BPC 157, BPC-157, and BPC157 interchangeably across 37+ peer-reviewed studies, confirming all three terms reference the same compound.
• HPLC analysis confirms that peptides labeled with or without hyphens show identical retention times and fragmentation patterns when synthesis quality and salt form are equivalent.
• Researchers should verify arginate salt form specification and purity exceeding 98% via third-party testing rather than relying on naming conventions to assess peptide quality.

What If: BPC157 Naming Scenarios

What If a Study Cites BPC-157 But My Supplier Lists BPC157?

Proceed with confidence if the certificate of analysis confirms the sequence, salt form, and purity match the published study's specifications. The hyphen difference does not indicate a different peptide. Verify instead that both the study and your supplier used arginate salt forms and that HPLC purity exceeds 98%. Studies published between 1993 and 2026 used all three naming formats (BPC 157, BPC-157, BPC157) to describe the identical 15-amino-acid sequence; journal editorial standards, not chemical distinctions, drove the variation. Cross-reference the CAS number (137525-51-0 for arginate) to confirm you're procuring the same compound cited in the literature.

What If My Peptide Arrives Labeled BPC 157 With a Space?

Treat it as the same peptide unless the certificate of analysis reveals unexpected molecular weight or fragmentation patterns. The space between "BPC" and "157" appeared in early University of Zagreb publications and remains common in European supplier catalogs. It reflects regional typesetting conventions, not a chemical variant. Focus verification efforts on confirming arginate salt form (more stable than acetate), peptide purity via HPLC (target >98%), and proper storage conditions (lyophilized powder at −20°C before reconstitution, 2–8°C after mixing with bacteriostatic water). The spacing in the name affects database indexing but not the peptide's amino acid backbone.

What If I See BPC-157 Marketed as a New Stabilized Version?

Request third-party testing documentation immediately. Marketing claims about "stabilized" or "enhanced" BPC-157 often refer to arginate versus acetate salt forms, not genuinely novel peptide engineering. The 15-amino-acid sequence cannot be stabilized beyond selecting the arginate counterion, which has been the standard synthesis approach since the late 1990s. If a supplier claims proprietary stabilization technology, ask for comparative stability data showing retention time advantages over standard arginate forms stored at 2–8°C. Legitimate advances would appear in peer-reviewed pharmaceutical science journals before commercial marketing materials. The hyphen alone signals nothing about stability. The counterion specification and HPLC purity data do.

The Blunt Truth About BPC157 Naming

Here's the honest answer: the hyphen debate is a distraction. BPC157, BPC-157, and BPC 157 are the same peptide. Anyone claiming otherwise is either misinformed or intentionally creating false product differentiation for marketing purposes. The variables that genuinely affect research outcomes. Arginate versus acetate salt form, synthesis purity above or below 98%, proper cold chain storage, and accurate reconstitution technique. Have nothing to do with whether a hyphen appears in the product name. Researchers waste time comparing BPC157 sources based on naming conventions when they should be comparing certificates of analysis for HPLC purity data, mass spectrometry confirmation of the 15-amino-acid sequence, and third-party verification that the peptide was synthesized as the stable arginate form. The supplement industry has seized on this confusion to sell "premium BPC-157" at markup prices justified solely by typographical choices, not by superior synthesis quality or verified potency. If a supplier cannot provide a certificate of analysis showing >98% purity via HPLC and confirming arginate salt form, the presence or absence of a hyphen is irrelevant. You're not getting research-grade peptide regardless of how it's spelled.

Verifying Peptide Identity Beyond the Name

Researchers ensuring they've procured authentic BPC157. Regardless of hyphen usage. Should request and review three core documents: the certificate of analysis (COA) showing HPLC purity data, mass spectrometry confirmation of molecular weight (1419.53 Da for the arginate form), and third-party lab verification that the peptide matches the expected 15-amino-acid sequence. The COA must specify purity as a percentage (target >98%) rather than generic "pharmaceutical grade" language, which carries no standardized definition in the peptide synthesis industry.

HPLC (high-performance liquid chromatography) separates the target peptide from synthesis byproducts, truncated sequences, and other impurities by measuring retention time as the sample passes through a chromatography column. A properly synthesized BPC 157 arginate batch shows a single dominant peak at the expected retention time, with aggregate impurity peaks totaling less than 2%. Mass spectrometry then confirms that the dominant peak's molecular weight matches the theoretical mass calculated from the Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val sequence plus the arginine counterion. Peptides failing either test. Regardless of whether the label reads BPC157 or BPC-157. Contain incorrect sequences, incomplete synthesis products, or degraded fragments that compromise dosing accuracy.

Real Peptides includes third-party COA documentation with every peptide shipment, confirming sequence accuracy and purity exceeding 98% via HPLC for compounds including BPC 157, TB 500 Thymosin Beta 4, and other research-grade peptides. The hyphen appears or disappears based on product listing conventions. The HPLC chromatogram and mass spec data remain constant. Researchers can explore the full range of verified research compounds at Real Peptides to compare synthesis quality standards across peptide categories.

The distinction that genuinely matters isn't BPC157 versus BPC-157. It's verified synthesis quality versus unverified claims, arginate stability versus acetate degradation, and transparent third-party testing versus proprietary "trust us" marketing. The hyphen is formatting; the certificate of analysis is evidence.